Released Nov 2, 2017, after the close
10-Q filed Nov 2, 2017, 33 days after period end · 0001558370-17-008004
Q3 2017 · 10-Q
Revenue$86.83M$86.83M +31.3% vs Q3 2016+33.4% vs Q2 2017
Net Income-$32.30M-$32.30M N/M vs Q3 2016N/M vs Q2 2017
EPS Diluted-$0.22-$0.22 N/M vs Q3 2016N/M vs Q2 2017
Operating Income-$19,434,000N/M
Operating Cash Flowderived-$31,242,000N/M
Free Cash Flowderived-$32,705,000N/M
Margins · derived
Operating margin-22.4%+20.4 pt vs Q3 2016
Net margin-37.2%+13.0 pt vs Q3 2016
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q3 2017 | Q3 2016 | Q3 2015 | Q3 2014 |
|---|---|---|---|---|
| Revenue | $86.83M | $66.11M | $39.57M | $16.92M |
| Net Income | -$32.30M | -$33.20M | — | — |
| EPS Diluted | -$0.22 | -$0.23 | -$0.33 | -$0.30 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ironwood Pharmaceuticals Inc · CIK 1446847 · Engraved from SEC EDGAR